| DESCRIPTION | - ABOU-ALFA et al., Journal of Clinical Oncology, (20060000), vol. 24, no. 27, pages 4441 - 4447 | - |
| DESCRIPTION | - ALTSCHUL et al., J. Mol. Biol., (19900000), vol. 215, pages 403 - 410 | - |
| DESCRIPTION | - AMSBERRY et al., J. Org. Chem., (19900000), vol. 55, page 5867 | - |
| DESCRIPTION | - CARILLO, SIAM J. Applied Math., (19880000), vol. 48, page 1073 | - |
| DESCRIPTION | - CARTER et al., PNAS, (19920000), vol. 89, page 4285 | - |
| DESCRIPTION | - CHALLITA-EID et al., Cancer Res., (20160000), vol. 76, no. 10, pages 3003 - 3013 | - |
| DESCRIPTION | - CHOTHIALESK, J. Mol., (19870000), vol. 196, page 901 | - |
| DESCRIPTION | - CHOTHIALESK, J. Mol. Biol, (19870000), vol. 196, pages 901 - 917 | - |
| DESCRIPTION | - CLACKSONWELLS, Science, (19950000), vol. 267, pages 383 - 386 | - |
| DESCRIPTION | - DOWNARD, J Mass Spectrom, (20000400), vol. 35, no. 4, pages 493 - 503 | - |
| DESCRIPTION | - EHRING H, Analytical Biochemistry, (19990000), vol. 267, no. 2, pages 252 - 259 | - |
| DESCRIPTION | - EISENHAUER et al., Eur. J. Cancer, (20090000), vol. 45, pages 228 - 247 | - |
| DESCRIPTION | - ENGEN, J. R.SMITH, D. L., Anal. Chem., (20010000), vol. 73, pages 256A - 265A | - |
| DESCRIPTION | - ERNST SCHERING, Res Found Workshop, (20040000), vol. 44, pages 149 - 67 | - |
| DESCRIPTION | - FAGERSTAM et al., Journal Of Molecular Recognition, (19900000), vol. 3, pages 208 - 14 | - |
| DESCRIPTION | - HAY et al., Bioorg. Med. Chem. Lett., (19990000), vol. 9, page 2237 | - |
| DESCRIPTION | - HUANG et al., Journal of Molecular Biology, (19980000), vol. 281, no. 1, pages 61 - 67 | - |
| DESCRIPTION | - JAKOBOVITZ et al., Nature, (19930000), vol. 362, page 255 | - |
| DESCRIPTION | - JONES et al., Nature, (19860000), vol. 321, page 522 | - |
| DESCRIPTION | - KINGSBURY et al., J. Med. Chem., (19840000), vol. 27, page 1447 | - |
| DESCRIPTION | - KISELARDOWNARD, Anal Chem., (19990501), vol. 71, no. 9, pages 1792 - 1801 | - |
| DESCRIPTION | - KROGER et al., Biosensors and Bioelectronics, (20020000), vol. 17, pages 937 - 944 | - |
| DESCRIPTION | - LEIPERT et al., Angew. Chem. Int. Ed., (19980000), vol. 37, pages 3308 - 3311 | - |
| DESCRIPTION | - LI et al., ACS Med. Chem. Lett., (20190000), vol. 10, no. 10, pages 1386 - 1392 | - |
| DESCRIPTION | - MITSUI et al., Jpn. J. Cancer Res., (19950000), vol. 86, pages 776 - 782 | - |
| DESCRIPTION | - M-RABET et al., Ann Oncol, (20170401), vol. 28, no. 4, pages 769 - 776 | - |
| DESCRIPTION | - MULLER, Meth. Enzymol., (19830000), vol. 92, pages 589 - 601 | - |
| DESCRIPTION | - NICE et al., J. Chromatogr., (19930000), vol. 646, pages 159 - 168 | - |
| DESCRIPTION | - Presta, Curr. Op. Struct. Biol., (19920000), vol. 2, page 593 | - |
| DESCRIPTION | - PRESTA et al., J. Immunol., (19930000), vol. 151, page 2623 | - |
| DESCRIPTION | - RABAT et al., Annals Onc, (20170000), vol. 28, pages 769 - 776 | - |
| DESCRIPTION | - REICHMANN et al., Nature, (19880000), vol. 332, page 20894 | - |
| DESCRIPTION | - REYMOND et al., J. Biol. Chem., (20010000), vol. 276, no. 46, pages 43205 - 15 | - |
| DESCRIPTION | - RODRIGUES et al., Chemistry Biology, (19950000), vol. 2, page 223 | - |
| DESCRIPTION | - SAITOPATTERSON, Methods, (19960600), vol. 9, no. 3, pages 516 - 24 | - |
| DESCRIPTION | - SAUNAL, J. Immunol. Methods, (19950000), vol. 183, pages 33 - 41 | - |
| DESCRIPTION | - TAKIGUCHI et al., Jpn. J. Cancer Res., (19970000), vol. 88, pages 760 - 769 | - |
| DESCRIPTION | - UC. DE JONGE et al., Invest New Drugs, (20040000), vol. 22, pages 329 - 333 | - |
| DESCRIPTION | - "Uniprot", Database accession no. Q96NY8 | - |
| DESCRIPTION | - "UniProt", Database accession no. Q96NY8-1 | - |
| DESCRIPTION | - Verhoeyen et Science, vol. 239, page 1534 | - |
| DESCRIPTION | - WANG et al., Nature, (19920000), vol. 355, pages 275 - 278 | - |
| DESCRIPTION | - WARD et al., Nature, (19890000), vol. 341, page 544 | - |
| DESCRIPTION | - WELLS, Proc Natl Acad Sci USA, (19960000), vol. 93, pages 1 - 6 | - |
| DESCRIPTION | - WOLCHOCK et al., Clinical Cancer Research, (20090000), vol. 15, pages 7412 - 7420 | - |
| DESCRIPTION | - ZEINDLER et al., Front. Med., (20190000), vol. 6, page 200 | - |
| EXAMINATION | - LIEW S T ET AL, "Design, synthesis and development of novel camptothecin drugs", CURRENT PHARMACEUTICAL DESIGN, BENTHAM SCIENCE PUBLISHERS, NL, (20080401), vol. 14, no. 11, doi:10.2174/138161208784246180, ISSN 1381-6128, pages 1078 - 1097, XP008111526 | |
| INTERNATIONAL-SEARCH-REPORT | - P. M. CHALLITA-EID ET AL, "Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models", CANCER RESEARCH, US, (20160515), vol. 76, no. 10, doi:10.1158/0008-5472.CAN-15-1313, ISSN 0008-5472, pages 3003 - 3013, XP055385700 [Y] 1-3,6-16,18-21 * abstract * * page 3004, column 2, paragraph 3 * * table 1 * * page 3012, column 2, paragraph 3 - paragraph 4 * | |
| OPPOSITION | - Anonymous, "FDA approves fam-trastuzumab deruxtecan-nxki for unresectable or metastatic HER2-positive breast cancer", FDA, (20191220), FDA, URL: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-her2-positive-breast-cancer, XP093316857 | - |
| OPPOSITION | - Anonymous, "PADCEV - ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS ", EMA, (20220413), EMA, URL: https://www.ema.europa.eu/en/documents/product-information/padcev-epar-product-information_en.pdf, XP093316885 | - |
| OPPOSITION | - Anonymous, "PADCEV TM (enfortumab vedotin-ejfv) for injection, for intravenous use - HIGHLIGHTS OF PRESCRIBING INFORMATION ", FDA, (20191201), FDA, URL: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761137s000lbl.pdf, XP093316846 | - |
| OPPOSITION | - D23 - Definitions of Cancer Progression and Cancer Recurrence, NHS Dictionary | - |
| OPPOSITION | - N N, "FDA grants accelerated approval to enfortumab vedotin-ejfv for metastatic urothelial cancer fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-enfortumab-vedotin-ejfvmetastatic-urothelial-cancer", US Food and Drug Administration, US, US, pages 1 - 2, URL: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-enfortumab-vedotin-ejfv-metastatic-urothelial-cancer, XP093307901 | - |
| OPPOSITION | - Chia C. S., "A Patent Review on FDA‐Approved Antibody‐Drug Conjugates, Their Linkers and Drug Payloads", ChemMedChem Communications, Wiley-VCH, DE, DE , (20220603), vol. 17, no. 11, doi:10.1002/cmdc.202200032, ISSN 1860-7179, pages 1 - 11, XP093305988 | |
| OPPOSITION | - Yaghoubi Sajad, Karimi Mohammad Hossein, Lotfinia Majid, Gharibi Tohid, Mahi‐birjand Motahare, Kavi Esmaeil, Hosseini Fahimeh, Sineh Sepehr Koushan, Khatami Mehrdad, Bagheri Nader, Abdollahpour‐alitappeh Meghdad, "Potential drugs used in the antibody-drug conjugate (ADC) architecture for cancer therapy", Journal of Cellular Physiology, Wiley Subscription Services, Inc., US, US , (20200101), vol. 235, no. 1, doi:10.1002/jcp.28967, ISSN 0021-9541, pages 31 - 64, XP093141806 | |
| OPPOSITION | - Nakada Takashi; Masuda Takeshi; Naito Hiroyuki; Yoshida Masao; Ashida Shinji; Morita Koji; Miyazaki Hideki; Kasuya Yuji; Ogitani Yusuke; Yamaguchi Junko; Abe Yuki; Honda Takeshi, "Novel antibody drug conjugates containing exatecan derivative-based cytotoxic payloads", Bioorganic & Medicinal Chemistry Letters, ELSEVIER, Amsterdam NL, Amsterdam NL , (20160208), vol. 26, no. 6, doi:10.1016/j.bmcl.2016.02.020, ISSN 0960-894X, pages 1542 - 1545, XP029436554 | |
| OPPOSITION | - Ogitani Yusuke, Abe Yuki, Iguchi Takuma, Yamaguchi Junko, Terauchi Tomoko, Kitamura Michiko, Goto Koichi, Goto Mayumi, Oitate Masataka, Yukinaga Hideo, Yabe Yoshiyuki, Nakada Takashi, Masuda Takeshi, Morita Koji, Agatsuma Toshinori, "Wide application of a novel topoisomerase I inhibitor-based drug conjugation technology", Bioorganic & Medicinal Chemistry Letters, ELSEVIER, Amsterdam NL, Amsterdam NL , (20161001), vol. 26, no. 20, doi:10.1016/j.bmcl.2016.08.082, ISSN 0960-894X, pages 5069 - 5072, XP055852728 | |
| OPPOSITION | - Julia Moukharskaya, Verschraegen Claire, "Topoisomerase 1 Inhibitors and Cancer Therapy", HEMATOLOGY - ONCOLOGY CLINICS OF NORTH AMERICA, W.B. SAUNDERS, US, US , (20120601), vol. 26, no. 3, doi:10.1016/j.hoc.2012.03.002, ISSN 0889-8588, pages 507 - 525, XP055683476 | |
| OPPOSITION | - Stephanie Alexander; Peter Friedl;, "Cancer invasion and resistance: interconnected processes of disease progression and therapy failure", Trends in Molecular Medicine, Elsevier Current Trends, GB, GB , vol. 18, no. 1, doi:10.1016/j.molmed.2011.11.003, ISSN 1471-4914, pages 13 - 26, XP028438261 | |
| OPPOSITION | - Delpeut Sebastien; Noyce Ryan S.; Richardson Christopher D., "The V domain of dog PVRL4 (nectin-4) mediates canine distemper virus entry and virus cell-to-cell spread", Virology, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL , (20140217), vol. 454, doi:10.1016/j.virol.2014.02.014, ISSN 0042-6822, pages 109 - 117, XP028846147 | |
| OPPOSITION | - Buecheler Jakob W., Winzer Matthias, Tonillo Jason, Weber Christian, Gieseler Henning, "Impact of Payload Hydrophobicity on the Stability of Antibody-Drug Conjugates", Molecular Pharmaceutics, American Chemical Society, US, US , (20180702), vol. 15, no. 7, doi:10.1021/acs.molpharmaceut.8b00177, ISSN 1543-8384, pages 2656 - 2664, XP055980396 | |
| OPPOSITION | - Patrick J. Burke, Senter Peter D., Meyer David W., Miyamoto Jamie B., Anderson Martha, Toki Brian E., Manikumar Govindarajan, Wani Mansukh C., Kroll David J., Jeffrey Scott C., "Design, Synthesis, and Biological Evaluation of Antibody−Drug Conjugates Comprised of Potent Camptothecin Analogues", Bioconjugate Chemistry, American Chemical Society, (20090617), vol. 20, no. 6, doi:10.1021/bc9001097, ISSN 10431802, pages 1242 - 1250, XP055079987 | |
| OPPOSITION | - Alain Beck, Liliane Goetsch, Charles Dumontet, Nathalie Corvaïa, "Strategies and challenges for the next generation of antibody-drug conjugates", Nature Reviews Drug Discovery, Nature Publishing Group, GB, GB , vol. 16, no. 5, doi:10.1038/nrd.2016.268, ISSN 1474-1776, pages 315 - 337, XP055552084 | |
| OPPOSITION | - Hunter Francis W.; Barker Hilary R.; Lipert Barbara; Rothé Françoise; Gebhart Géraldine; Piccart-Gebhart Martine J.; Sotiriou Christos; Jamieson Stephen M. F., "Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer", British Journal of Cancer, Nature Publishing Group UK, London, London, (20191216), vol. 122, no. 5, doi:10.1038/s41416-019-0635-y, ISSN 0007-0920, pages 603 - 612, XP037049268 | |
| OPPOSITION | - Anami Yasuaki, Yamazaki Chisato M., Xiong Wei, Gui Xun, Zhang Ningyan, An Zhiqiang, Tsuchikama Kyoji, "Glutamic acid-valine-citrulline linkers ensure stability and efficacy of antibody-drug conjugates in mice", Nature Communications, vol. 9, no. 1, doi:10.1038/s41467-018-04982-3, XP093084676 | |
| OPPOSITION | - Modi Shanu, Saura Cristina, Yamashita Toshinari, Park Yeon Hee, Kim Sung-Bae, Tamura Kenji, Andre Fabrice, Iwata Hiroji, Ito Yoshinori, Tsurutani Junji, Sohn Joohyuk, Denduluri Neelima, Perrin Christophe, Aogi Kenjiro, Tokunaga Eriko, Im Seock-Ah, Lee Keun Seok, Hurvitz Sara A., Cortes Javier, Lee Caleb, Chen Shuquan, Zhang Lin, Shahidi Javad, Yver Antoine, Krop Ian, "Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer", New England Journal of Medicine, Massachusetts Medical Society, United States, United States, (20200213), vol. 382, no. 7, doi:10.1056/NEJMoa1914510, ISSN 0028-4793, pages 610 - 621, XP093316851 | |
| OPPOSITION | - M. M-Rabet, O. Cabaud, E. Josselin, P. Finetti, R. Castellano, A. Farina, E. Agavnian-Couquiaud, G. Saviane, Y. Collette, P. Viens, A. Gonçalves, C. Ginestier, E. Charafe-Jauffret, D. Birnbaum, D. Olive, F. Bertucci, M. Lopez, "Nectin-4: a new prognostic biomarker for efficient therapeutic targeting of primary and metastatic triple-negative breast cancer", (20170401), vol. 28, no. 4, doi:10.1093/annonc/mdw678, pages 769 - 776, XP055762552 | |
| OPPOSITION | - Yusuke Ogitani, Katsunobu Hagihara, Masataka Oitate, Hiroyuki Naito, Toshinori Agatsuma, "Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity", CANCER SCIENCE, JAPANESE CANCER ASSOCIATION, TOKYO, JP, JP , (20160701), vol. 107, no. 7, doi:10.1111/cas.12966, ISSN 1347-9032, pages 1039 - 1046, XP055690751 | |
| OPPOSITION | - R. JAGER; P. CHEVERTON; K. TAMANOI; J. COYLE; M. DUCHARME; N. SAKAMOTO; M. SATOMI; M. SUZUKI, "DX‐8951f: Summary of Phase I Clinical Trials", Annals of the New York Academy of Sciences, New York Academy of Sciences., US, US , (20060125), vol. 922, no. 1, doi:10.1111/j.1749-6632.2000.tb07044.x, ISSN 0077-8923, pages 260 - 273, XP071393785 | |
| OPPOSITION | - Reches Adi, Ophir Yael, Stein Natan, Kol Inbal, Isaacson Batya, Charpak Amikam Yoav, Elnekave Afek, Tsukerman Pinchas, Kucan Brlic Paola, Lenac Tihana, Seliger Barbara, Jonjic Stipan, Mandelboim Ofer, "Nectin4 is a novel TIGIT ligand which combines checkpoint inhibition and tumor specificity", Journal for ImmunoTherapy of Cancer, BioMed Central, London, GB, GB , (20200407), vol. 8, no. 1, doi:10.1136/jitc-2019-000266, ISSN 2051-1426, page e000266, XP093235482 | |
| OPPOSITION | - P. M. Challita-Eid, D. Satpayev, P. Yang, Z. An, K. Morrison, Y. Shostak, A. Raitano, R. Nadell, W. Liu, D. R. Lortie, L. Capo, A. Verlinsky, M. Leavitt, F. Malik, H. Avina, C. I. Guevara, N. Dinh, S. Karki, B. S. Anand, D. S. Pereira, I. B. J. Joseph, F. Donate, D. R. Stover, "Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models", Cancer Research, American Association for Cancer Research, (20160515), vol. 76, no. 10, doi:10.1158/0008-5472.CAN-15-1313, ISSN 0008-5472, pages 3003 - 3013, XP055385700 | |
| OPPOSITION | - Li Fu, Emmerton Kim K., Jonas Mechthild, Zhang Xinqun, Miyamoto Jamie B., Setter Jocelyn R., Nicholas Nicole D., Okeley Nicole M., Lyon Robert P., Benjamin Dennis R., Law Che-Leung, "Intracellular Released Payload Influences Potency and Bystander-Killing Effects of Antibody-Drug Conjugates in Preclinical Models", Cancer Research, American Association for Cancer Research, (20160501), vol. 76, no. 9, doi:10.1158/0008-5472.CAN-15-1795, ISSN 0008-5472, pages 2710 - 2719, XP093316860 | |
| OPPOSITION | - Sara García-Alonso, Alberto Ocaña, Atanasio Pandiella, "Resistance to Antibody-Drug Conjugates", Cancer Research, American Association for Cancer Research, (20180501), vol. 78, no. 9, doi:10.1158/0008-5472.CAN-17-3671, ISSN 0008-5472, pages 2159 - 2165, XP055601774 | |
| OPPOSITION | - Amiri-Kordestani Laleh, Blumenthal Gideon M., Xu Qiang Casey, Zhang Lijun, Tang Shenghui W., Ha Linan, Weinberg Wendy C., Chi Bo, Candau-Chacon Reyes, Hughes Patricia, Russell Anne M., Miksinski Sarah Pope, Chen Xiao Hong, Mcguinn W. David, Palmby Todd, Schrieber Sarah J., Liu Qi, Wang Jian, Song Pengfei, Mehrotra Nitin, Skarupa Lisa, Clouse Kathleen, Al-Hakim Ali, Sridhara Rajeshwari, Ibrahim Amna, Justice Robert, Pazdur Richard, Cortazar Patricia, "FDA Approval: Ado-Trastuzumab Emtansine for the Treatment of Patients with HER2-Positive Metastatic Breast Cancer", Clinical cancer research, American Association for Cancer Research Inc, (20140901), vol. 20, no. 17, doi:10.1158/1078-0432.CCR-14-0012, ISSN 1078-0432, pages 4436 - 4441, XP055881003 | |
| OPPOSITION | - Y. Ogitani, T. Aida, K. Hagihara, J. Yamaguchi, C. Ishii, N. Harada, M. Soma, H. Okamoto, M. Oitate, S. Arakawa, T. Hirai, R. Atsumi, T. Nakada, I. Hayakawa, Y. Abe, T. Agatsuma, "DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1", Clinical cancer research, American Association for Cancer Research Inc, (20161015), vol. 22, no. 20, doi:10.1158/1078-0432.CCR-15-2822, ISSN 1078-0432, pages 5097 - 5108, XP055482007 | |
| OPPOSITION | - Klümper Niklas, Ralser Damian J., Ellinger Jörg, Roghmann Florian, Albrecht Julia, Below Eduard, Alajati Abdullah, Sikic Danijel, Breyer Johannes, Bolenz Christian, Zengerling Friedemann, Erben Philipp, Schwamborn Kristina, Wirtz Ralph M., Horn Thomas, Nagy Dora, Toma Marieta, Kristiansen Glen, Büttner Thomas, Hahn Oliver, Grünwald Viktor, Darr Christopher, Erne Eva, Rausch Steffen, Bedke Jens, Schlack Katrin, Abbas Mahmoud, Zschäbitz Stefanie, Schwab Constantin, Mustea Alexander, Adam Patrick, Manseck Andreas, Wullich Bernd, Ritter Manuel, Hartmann Arndt, Gschwend Jürgen, Weichert Wilko, Erlmeier Franziska, Hölzel Michael, Eckstein Markus, "Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance", Clinical cancer research, American Association for Cancer Research Inc, (20230414), vol. 29, no. 8, doi:10.1158/1078-0432.CCR-22-1764, ISSN 1078-0432, pages 1496 - 1505, XP093316861 | |
| OPPOSITION | - Chen Robert, Hou Jessie, Newman Edward, Kim Young, Donohue Cecile, Liu Xueli, Thomas Sandra H., Forman Stephen J., Kane Susan E., "CD30 Downregulation, MMAE Resistance, and MDR1 Upregulation Are All Associated with Resistance to Brentuximab Vedotin", Molecular Cancer Therapeutics, American Association for Cancer Research, US, US , (20150601), vol. 14, no. 6, doi:10.1158/1535-7163.MCT-15-0036, ISSN 1535-7163, pages 1376 - 1384, XP093316850 | |
| OPPOSITION | - Loganzo Frank, Sung Matthew, Gerber Hans-Peter, "Mechanisms of Resistance to Antibody-Drug Conjugates", Molecular Cancer Therapeutics, American Association for Cancer Research, US, US , (20161201), vol. 15, no. 12, doi:10.1158/1535-7163.MCT-16-0408, ISSN 1535-7163, pages 2825 - 2834, XP093316854 | |
| OPPOSITION | - Cabaud Olivier, Berger Ludovic, Crompot Emerence, Adélaide José, Finetti Pascal, Garnier Sèverine, Guille Arnaud, Carbuccia Nadine, Farina Anne, Agavnian Emilie, Chaffanet Max, Gonçalves Anthony, Charafe-Jauffret Emmanuelle, Mamessier Emilie, Birnbaum Daniel, Bertucci François, Lopez Marc, "Overcoming Resistance to Anti-Nectin-4 Antibody-Drug Conjugate", Molecular Cancer Therapeutics, American Association for Cancer Research, US, US , (20220705), vol. 21, no. 7, doi:10.1158/1535-7163.MCT-22-0013, ISSN 1535-7163, pages 1227 - 1235, XP093316877 | |
| OPPOSITION | - Lopez Marc, Crompot Emerence, Josselin Emmanuelle, Farina Anne, Rubis Marion, Castellano Remy, Fares Joanna, Wehbe Maria, Collette Yves, Charafe Emmanuelle, Blanchin Stéphanie, Romagne François, Pálfi Anikó, Hechler Torsten, Pahl Andreas, Azim Hatem A., Lhospice Florence, Mamessier Emilie, Bertucci François, Elands Jack, Préville Xavier, Olive Daniel, "ETx-22, a Novel Nectin-4-Directed Antibody-Drug Conjugate, Demonstrates Safety and Potent Antitumor Activity in Low-Nectin-4-Expressing Tumors", Cancer research communications, American Association for Cancer Research, (20241101), vol. 4, no. 11, doi:10.1158/2767-9764.CRC-24-0176, ISSN 2767-9764, pages 2998 - 3012, XP093316874 | |
| OPPOSITION | - Rosenberg Jonathan E, O 'donnell Peter H, Balar Arjun V, Mcgregor Bradley A, Heath Elisabeth I, Yu Evan Y, Galsky Matthew D, Hahn Noah M, Gartner Elaina M, Pinelli Juan M, Pa-C, 11 Mmsc, Liang Shang-Ying, Melhem-Bertrandt Amal, Petrylak Daniel P, "Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy", 2024 ASCO Gastrointestinal Cancers Symposium, Poster L3, Poster L3, (20191010), vol. 37, no. 29, doi:10.1200/JCO.19.01140, ISSN 0732-183X, pages 2592 - 2600, XP055831081 | |
| OPPOSITION | - You Fei, Gao Changshou, "Topoisomerase Inhibitors and Targeted Delivery in Cancer Therapy", CURRENT TOPICS IN MEDICINAL CHEMISTRY, Bentham Science Publishers Ltd.HILVERSUM, NL, NL , (20190620), vol. 19, no. 9, doi:10.2174/1568026619666190401112948, ISSN 1568-0266, pages 713 - 729, XP093316865 | |
| OPPOSITION | - Hammood Manar, Craig Andrew, Leyton Jeffrey, "Impact of Endocytosis Mechanisms for the Receptors Targeted by the Currently Approved Antibody-Drug Conjugates (ADCs)—A Necessity for Future ADC Research and Development", Pharmaceuticals, M D P I AG, CH, CH , vol. 14, no. 7, doi:10.3390/ph14070674, ISSN 1424-8247, page 674, XP093316870 | |
